FDA update on CBD offers no timetable for action

FDA says it will soon reopen the docket for comments on how it should regulate hemp-derived cannabidiol (CBD) and is considering a “risk-based enforcement policy” to address concerns about the proliferation of CBD products, but the agency still lacks a timetable for when it might lay out a regulatory pathway for foods or supplements that contain the non-psychoactive cannabis ingredient.


Leave a Reply